Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | AKT1 | P31749 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12484478 | 0.91 | MAPT (0.57) | MAPTCTSLCTSSCTSKMAPK1 | |
| Hydrochloric Acid SCHEMBL17698366 | 0.90 | MAPT (0.56) | MAPTCTSLCTSSCTSKMAPK1 | |
| SCHEMBL12485485 | 0.89 | MAPT (0.55) | MAPTCTSLCTSSCTSKMAPK1 | |
| SCHEMBL12486543 | 0.88 | BLM (0.52) | MAPTMAPK1KDM4ECYP3A4CYP1A2 | |
| SCHEMBL12486039 | 0.84 | MAPT (0.67) | MAPTCTSLCTSSCTSKMAPK1 | |
| SCHEMBL13950760 | 0.81 | MAPT (0.60) | MAPTCTSLCTSSCTSKMAPK1 | |
| SCHEMBL3450648 | 0.81 | MAPT (0.62) | MAPTCTSLCTSSCTSKMAPK1 | |
| SCHEMBL12486223 | 0.80 | GALR2 (0.48) | MAPTMAPK1LMNAKDM4EHPGD | |
| SCHEMBL6993523 | 0.79 | GRIN2D (0.57) | MAPK1KDM4EAURKAAURKBDHFR | |
| SCHEMBL12486368 | 0.79 | GALR2 (0.50) | MAPTMAPK1KDM4ESMN1; SMN2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10640490-B2 | Diaminopyrimidine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2020-05-05 | — | — | US | claimed |
| US-20180072705-A1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2018-03-15 | — | — | US | claimed |
| US-9850227-B2 | Diaminopyrimidine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2017-12-26 | — | — | US | claimed |
| EP-2678331-B1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORP (KR) | 2016-04-27 | — | — | EP | claimed |
| CN-103391935-B | Diaminopyrimidine derivatives and process for preparing same | Liu Hanyangxing (KR) | 2015-12-23 | — | — | CN | claimed |
| EP-2678331-A2 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Yuhan Corporation (KR) | 2014-01-01 | — | — | EP | claimed |
| US-20130331377-A1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2013-12-12 | — | — | US | claimed |
| CN-103391935-A | Diaminopyrimidine derivatives and process for preparing same | YUHAN CORP | 2013-11-13 | — | — | CN | claimed |
| WO-2012115478-A2 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2012-08-30 | — | — | WO | claimed |
| US-10640490-B2 | Diaminopyrimidine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2020-05-05 | — | — | US | disclosed |
| US-20180072705-A1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2018-03-15 | — | — | US | disclosed |
| US-9850227-B2 | Diaminopyrimidine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2017-12-26 | — | — | US | disclosed |
| EP-2678331-B1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORP (KR) | 2016-04-27 | — | — | EP | disclosed |
| CN-103391935-B | Diaminopyrimidine derivatives and process for preparing same | Liu Hanyangxing (KR) | 2015-12-23 | — | — | CN | disclosed |
| EP-2678331-A2 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Yuhan Corporation (KR) | 2014-01-01 | — | — | EP | disclosed |
| US-20130331377-A1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2013-12-12 | — | — | US | disclosed |
| CN-103391935-A | Diaminopyrimidine derivatives and process for preparing same | YUHAN CORP | 2013-11-13 | — | — | CN | disclosed |
| WO-2012115478-A2 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2012-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331377-A1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | HRH2, GIPR, SSTR4 | MAPT 3132/4885CTSL 4182/4885CTSS 3052/4885 |
| US-10640490-B2 | Diaminopyrimidine derivatives and processes for the preparation thereof | HRH2, GIPR, SSTR4 | MAPT 3132/4885CTSL 4182/4885CTSS 3052/4885 |
| US-20180072705-A1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | HRH2, GIPR, SSTR4 | MAPT 3132/4885CTSL 4182/4885CTSS 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.